MeiraGTx Holdings plc (MGTX)
NASDAQ: MGTX · Real-Time Price · USD
8.31
-0.18 (-2.12%)
At close: Jul 24, 2025, 4:00 PM
8.25
-0.06 (-0.72%)
After-hours: Jul 24, 2025, 7:39 PM EDT

Company Description

MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases.

The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.

It is also developing AAV-AQP1 in Phase 2 trial for radiation-induced grade 2/3 radiation-induced xerostomia, as well as in Phase ½ trial for Sjogren’s syndrome; AAV-GAD in Phase 2 trial for Parkinson’s disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase 2 trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4.

In addition, the company’s products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer’s disease, and wet and dry neovascular age related macular degeneration.

Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain.

The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson’s disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system.

MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.

MeiraGTx Holdings plc
MeiraGTx Holdings logo
CountryUnited States
Founded2015
IndustryBiotechnology
SectorHealthcare
Employees381
CEOAlexandria Forbes

Contact Details

Address:
450 East 29th Street, 14th Floor
New York, New York 10016
United States
Phone646 860 7985
Websitemeiragtx.com

Stock Details

Ticker SymbolMGTX
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001735438
CUSIP NumberG59665102
ISIN NumberKYG596651029
Employer ID98-1448305
SIC Code2836

Key Executives

NamePosition
Dr. Alexandria Forbes Ph.D.Chief Executive Officer, President and Director
Richard Brian Giroux B.A.Chief Operating Officer and Chief Financial Officer
Dr. Stuart Naylor Ph.D.Chief Development Officer
Robert J. Wollin J.D.General Counsel and Secretary
Dr. Michel Michaelides M.D.Head of Clinical Ophthalmology
Christine Elise SheehySenior Vice President of Global Integration
Tim RandallSenior Vice President of Risk and Internal Controls
Dr. Robert K. Zeldin M.D.Chief Medical Officer
Dr. David Rubinstein Ph.D.Senior Vice President of Business Development

Latest SEC Filings

DateTypeTitle
Jul 22, 2025144Filing
Jul 8, 2025144Filing
Jun 26, 20258-KCurrent Report
Jun 17, 20258-KCurrent Report
May 14, 2025SCHEDULE 13G/AFiling
May 13, 202510-QQuarterly Report
May 13, 20258-KCurrent Report
May 9, 20258-KCurrent Report
Apr 30, 2025ARSFiling
Apr 30, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material